Impact of corneal cross-linking on drug penetration in an ex vivo porcine eye model

Cornea

Volumn 31, Issue 3, 2012, Pages 222-226

  Tschopp, Markus ^a   Stary, Johannes ^a   Frueh, Beatrice E ^a   Thormann, Wolfgang ^b   De Smet, Julie ^c   Van Bocxlaer, Jan ^c   Tappeiner, Christoph ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Corneal penetration; Cross linking; Ofloxacin; Voriconazole

Indexed keywords

OFLOXACIN; RIBOFLAVIN; VORICONAZOLE;

ANTERIOR EYE CHAMBER; ANTERIOR EYE CHAMBER DEPTH; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; CORNEA CROSS LINKING; CORNEA PERMEABILITY; CORNEA THICKNESS; DRUG DETERMINATION; DRUG PENETRATION; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTERIOR CHAMBER; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AQUEOUS HUMOR; CORNEA; MODELS, ANIMAL; OFLOXACIN; PHOTOSENSITIZING AGENTS; PYRIMIDINES; RANDOM ALLOCATION; RIBOFLAVIN; SWINE; TRIAZOLES; ULTRAVIOLET RAYS;

EID: 84857218216     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0B013E31823E29D5     Document Type: Article

References (29)

1. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620-627. (Pubitemid 36457967)
2. Caporossi A, Baiocchi S, Mazzotta C, et al. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006;32:837-845. (Pubitemid 43831548)
3. Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008;24:S720-S725.
4. Wollensak G, Iomdina E. Long-term biomechanical properties of rabbit cornea after photodynamic collagen crosslinking. Acta Ophthalmol. 2009;87:48-51.
5. Wollensak G, Wilsch M, Spoerl E, et al. Collagen fiber diameter in the rabbit cornea after collagen crosslinking by riboflavin/UVA. Cornea. 2004;23:503-507. (Pubitemid 38857010)
6. Kolli S, Aslanides IM. Safety and efficacy of collagen crosslinking for the treatment of keratoconus. Expert Opin Drug Saf. 2010;9:949-957.
7. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008;34:796-801. (Pubitemid 351615507)
8. Wollensak G, Spörl E, Reber F, et al. Corneal endothelial cytotoxicity of riboflavin/UVA treatment in vitro. Ophthalmic Res. 2003;35:324-328. (Pubitemid 38032509)
9. Wollensak G, Spörl E, Seiler T. Treatment of keratoconus by collagen cross linking [in German]. Ophthalmologe. 2003;100:44-49. (Pubitemid 36717241)
10. Pitts DG, Cullen AP, Hacker PD. Ocular effects of ultraviolet radiation from 295 to 365 nm. Invest Ophthalmol Vis Sci. 1977;16:932-939. (Pubitemid 8201834)
11. Stewart JM, Schultz DS, Lee OT, et al. Collagen cross-links reduce corneal permeability. Invest Ophthalmol Vis Sci. 2009;50:1606-1612.
12. Tripathi RC, Millard CB, Tripathi BJ. Protein composition of human aqueous humor: SDS-PAGE analysis of surgical and post-mortem samples. Exp Eye Res. 1989;48:117-130. (Pubitemid 19046253)
13. De Smet J, Boussery K, Colpaert K, et al. Pharmacokinetics of fluoroquinolones in critical care patients: a bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:961-967.
14. Theurillat R, Zimmerli S, Thormann W. Determination of voriconazole in human serum and plasma by micellar electrokinetic chromatography. J Pharm Biomed Anal. 2010;53:1313-1318.
15. Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol. 2006;17:356-360. (Pubitemid 44215044)
16. Tuft SJ, Moodaley LC, Gregory WM, et al. Prognostic factors for the progression of keratoconus. Ophthalmology. 1994;101:439-447. (Pubitemid 24100567)
17. Ibrahim YW, Boase DL, Cree IA. Epidemiological characteristics, predisposing factors and microbiological profiles of infectious corneal ulcers: the Portsmouth corneal ulcer study. Br J Ophthalmol. 2009;93: 1319-1324.
18. Edwards A, Prausnitz MR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J. 1998;44:214-225. (Pubitemid 128485306)
19. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998; 87:1479-1488.
20. Faber C, Scherfig E, Prause JU, et al. Corneal thickness in pigs measured by ultrasound pachymetry in vivo. Scand J Lab Anim Sci. 2008;35:39-43. (Pubitemid 351715674)
21. Koch HR, Kulus SC, Roessler M, et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg. 2005;31:1377-1385. (Pubitemid 41583354)
22. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004;23:255-263. (Pubitemid 38401902)
23. Fukuda M, Inoue A, Sasaki K, et al. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol. 2004;48:93-96. (Pubitemid 38453779)
24. Wei LC, Tsai TC, Tsai HY, et al. Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application. Curr Eye Res. 2010;35:573-579.
25. Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010;29:1353-1358.
26. Moran H, Malmsjö M, Mortensen J, et al. Riboflavin and ultraviolet A collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010;29:102-104.
27. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability I: evaluation of fluorometholone. J Pharm Sci. 1975;64:931-936.
28. Hanna C, Massey JY, Hendrickson RO, et al. Ocular penetration of topical chloramphenicol in humans. Arch Ophthalmol. 1978;96: 1258-1261. (Pubitemid 8372328)
29. Massey JY, Hanna C, Goodart R, et al. Effect of drug vehicle on human ocular retention of topically applied tetracycline. Am J Ophthalmol. 1976;81:151-156.